114 related articles for article (PubMed ID: 20531301)
1. Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1.
Dash R; Su ZZ; Lee SG; Azab B; Boukerche H; Sarkar D; Fisher PB
Oncogene; 2010 Aug; 29(31):4412-23. PubMed ID: 20531301
[TBL] [Abstract][Full Text] [Related]
2. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
3. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
4. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation.
Yang HS; Knies JL; Stark C; Colburn NH
Oncogene; 2003 Jun; 22(24):3712-20. PubMed ID: 12802278
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
Li JJ; Dong Z; Dawson MI; Colburn NH
Cancer Res; 1996 Feb; 56(3):483-9. PubMed ID: 8564958
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells.
Fiucci G; Ravid D; Reich R; Liscovitch M
Oncogene; 2002 Apr; 21(15):2365-75. PubMed ID: 11948420
[TBL] [Abstract][Full Text] [Related]
7. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
Su ZZ; Austin VN; Zimmer SG; Fisher PB
Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
[TBL] [Abstract][Full Text] [Related]
8. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
9. AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation.
Madireddi MT; Dent P; Fisher PB
J Cell Physiol; 2000 Oct; 185(1):36-46. PubMed ID: 10942517
[TBL] [Abstract][Full Text] [Related]
10. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
Jansen AP; Colburn NH; Verma AK
Oncogene; 1999 Oct; 18(42):5806-13. PubMed ID: 10523861
[TBL] [Abstract][Full Text] [Related]
11. Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Fralix KD; Zhao S; Venkatasubbarao K; Freeman JW
J Cell Physiol; 2003 Jan; 194(1):88-99. PubMed ID: 12447993
[TBL] [Abstract][Full Text] [Related]
12. Induction of transformation progression in type 5 adenovirus-transformed rat embryo cells by a cloned protein kinase C beta 1 gene and reversal of progression by 5-azacytidine.
Su ZZ; Shen R; O'Brian CA; Fisher PB
Oncogene; 1994 Apr; 9(4):1123-32. PubMed ID: 7510863
[TBL] [Abstract][Full Text] [Related]
13. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis.
Wang J; Yang Y; Xia HH; Gu Q; Lin MC; Jiang B; Peng Y; Li G; An X; Zhang Y; Zhuang Z; Zhang Z; Kung HF; Wong BC
Gastroenterology; 2007 Mar; 132(3):1066-76. PubMed ID: 17383428
[TBL] [Abstract][Full Text] [Related]
14. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation.
Yang HS; Jansen AP; Nair R; Shibahara K; Verma AK; Cmarik JL; Colburn NH
Oncogene; 2001 Feb; 20(6):669-76. PubMed ID: 11314000
[TBL] [Abstract][Full Text] [Related]
15. Influence of the glucocorticoid receptor on c-fos inducibility in activated ras-containing mouse lung cells.
Johnson TA; Li J; Beer DG
Mol Carcinog; 1996 Oct; 17(2):70-7. PubMed ID: 8890955
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.
Liu Y; Ludes-Meyers J; Zhang Y; Munoz-Medellin D; Kim HT; Lu C; Ge G; Schiff R; Hilsenbeck SG; Osborne CK; Brown PH
Oncogene; 2002 Oct; 21(50):7680-9. PubMed ID: 12400010
[TBL] [Abstract][Full Text] [Related]
17. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.
Hommura F; Katabami M; Leaner VD; Donninger H; Sumter TF; Resar LM; Birrer MJ
Mol Cancer Res; 2004 May; 2(5):305-14. PubMed ID: 15192124
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells.
Briggs J; Chamboredon S; Castellazzi M; Kerry JA; Bos TJ
Oncogene; 2002 Oct; 21(46):7077-91. PubMed ID: 12370830
[TBL] [Abstract][Full Text] [Related]
19. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression.
Ramos-Nino ME; Timblin CR; Mossman BT
Cancer Res; 2002 Nov; 62(21):6065-9. PubMed ID: 12414630
[TBL] [Abstract][Full Text] [Related]
20. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
Watts RG; Huang C; Young MR; Li JJ; Dong Z; Pennie WD; Colburn NH
Oncogene; 1998 Dec; 17(26):3493-8. PubMed ID: 10030673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
